References
1. O’Brien MT et. al. Diagnosis and treatment of the pelvic congestion syndrome. Journal of Vascular Surgery: Venous and Lymphatic Disorder. 2015; 3:96–106.
2. British Society of Interventional Radiology (BSIR)
3. Dragan Milic (Clinical centre of Nis, Nis, Serbia) at the European Venous Forum (EVF; 28–30 June 2018, Athens, Greece).
4. Bendek, Boleslaw et.al. Comprehensive Review of Pelvic Congestion Syndrome; causes, symptoms, treatment options. Current Opinion in Obstetrics and Gynecology. 2020; 32:237-242.
5. Omur Taksin, Levent Sahin, Sergey G. Gavrillov, Zaza Lazarashvili, Medical treatment of pelvic congestion syndrome. Phlebolymphology. 2016; Volume 23, Number 3.,
6. Bookwalter et.al radiographics.rsna.org Volume 39 Number 2
7. Tu FF, Hahn D, Steege JF. Pelvic congestion syndrome-associated pelvic pain: a systematic review of diagnosis and management. Obstet Gynecol Surv. 2010 May; 65(5):332-40.
8. Daniels JP, et al. Effectiveness of embolization or sclerotherapy of pelvic veins for reducing chronic pelvic pain: a systematic review. J. Vase Radiol. 2016 Oct; 1478-1486.e8.
9. Simsek M, Burak F, Taskin O. Effects of micronized purified flavonoid fraction (Daflon) on pelvic pain in women with laparoscopically diagnosed pelvic congestion syndrome: a randomized crossover trial. Clin. Exp. Obstet Gynecol. 2007; 34:96-98
10. Gavrilov SG, Karalkin AV, Moskalenko EP, Beliaeva ES, Ianina AM, Kirienko AI. Micronized purified flavonoid fraction in treatment of pelvic varicose veins [in Russian]. Angiol Sosud Khir. 2012; 18(1):71-75.
11. Antignani PL, Lazarashvili Z, Monedero JL, et al. Diagnosis and treatment of pelvic congestion syndrome: UIP consensus document. Int Angiol 2019; 38:265–283.